drugset / Trial / NCT03780140

Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections

NCT03780140

Expanded access Approved for marketing Shionogi

Summary

Expanded access may be provided for cefiderocol for qualified patients who have limited treatment options and are not eligible for a clinical trial.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cefiderocol Small molecule Intravenous